Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-04-04Clinical Trial Update: JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation [Phase 3]
Phase 3 trial update: JAB-21822 in combination with JAB-3312 versus standard of care in first-line treatment of advanced non-small cell lung…
-
CLINICAL_TRIALS research · 2025-04-04Clinical Trial Update: Study on c-Met Targeted PET/CT Imaging in NSCLC [NA]
A clinical trial is evaluating a c-Met targeted PET/CT imaging tracer in non-small cell lung cancer. The study is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-04-03Clinical Trial Update: A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA) [Phase 3]
Results from the Phase 3 LAURA trial evaluating osimertinib after chemoradiation in stage III unresectable non-small cell lung cancer have b…
-
CLINICAL_TRIALS trial_result · 2025-04-03Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer [Phase 1]
Phase 1 trial evaluating alflutinib in advanced non-small cell lung cancer reports safety, tolerability, pharmacokinetics and anti-tumor act…
-
CLINICAL_TRIALS trial_result · 2025-04-03Clinical Trial Update: Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M [Phase 2]
A Phase 2 trial evaluating alflutinib in EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer has been terminated. …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-04-03Clinical Trial Update: A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC [Phase 2]
A Phase 2 clinical trial update on PM8002 (anti-PD-L1/VEGF) in combination with chemotherapy for non-small cell lung cancer, currently activ…
-
CLINICAL_TRIALS research · 2025-04-03Clinical Trial Update: Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab [Phase 4]
Phase 4 clinical trial evaluating chemoradiotherapy with surgery followed by consolidation durvalumab for non-small cell lung cancer (stage …
-
CLINICAL_TRIALS other · 2025-04-03Clinical Trial Update: Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients [Phase 2, Phase 3]
A Phase 2/3 clinical trial is planned to evaluate the combination of glumetinib with osimertinib for recurrent or metastatic non-small cell …
-
CLINICAL_TRIALS research · 2025-04-03Clinical Trial Update: Quality of Life as a Predictor of OS and PFS in Patients With Lung Cancer
The trial update discusses analyzing quality of life as a potential predictor of overall survival and progression-free survival in patients …
-
CLINICAL_TRIALS research · 2025-04-03Clinical Trial Update: Integrating Surgery and Radiotherapy Following Tislelizumab-based Conversion Therapy in N3-Stage III NSCLC [Phase 2]
Phase 2 trial update evaluating tislelizumab-based conversion therapy followed by surgery and radiotherapy for N3-stage III non-small cell l…
-
CLINICAL_TRIALS trial_result · 2025-04-03Clinical Trial Update: AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations [NA]
The AST2818 trial in advanced non-small cell lung cancer with EGFR mutations has been terminated; no further results are provided in the upd…
-
CLINICAL_TRIALS research · 2025-04-03Clinical Trial Update: A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC) [Phase 2]
A Phase 2 study is evaluating the safety and efficacy of PLB1004 in patients with EGFR exon 20 insertion-mutant advanced or metastatic non-s…
-
CLINICAL_TRIALS research · 2025-04-03Clinical Trial Update: Genotyping of Ebus-tbna Supernant Cell-free Dna in Nsclc
A clinical trial update indicates a study on genotyping endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) superna…
-
CLINICAL_TRIALS trial_result · 2025-04-02Clinical Trial Update: Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients [Phase 2]
A Phase 2 neoadjuvant trial for EGFR-mutated non-small cell lung cancer (Neo-DIANA) was terminated, with results posted in 2025.
-
CLINICAL_TRIALS trial_result · 2025-04-02Clinical Trial Update: A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies [Phase 1, Phase 2]
Phase 1/2 open-label study evaluating Alomfilimab (KY1044) alone and with atezolizumab in multiple advanced cancers. The trial was terminate…
-
CLINICAL_TRIALS trial_result · 2025-04-02Clinical Trial Update: TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors [Phase 1, Phase 2]
Clinical trial update for TT-10 and TT-4 (Portage Biotech) exploring single-agent and combination therapy in advanced solid tumors, with rec…
-
CLINICAL_TRIALS research · 2025-04-02Clinical Trial Update: TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO
This clinical trial update announces ongoing recruitment for the TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO study led by Un…
-
CLINICAL_TRIALS research · 2025-04-02Clinical Trial Update: Assessment of PET Tracers to Evaluate T Cell Change and Activation in Relation to Immunotherapy Treatment Response in Non-Small Cell Lung Cancer [NA]
Clinical trial evaluating PET tracers to assess T cell changes and activation in relation to immunotherapy response in non-small cell lung c…
-
CLINICAL_TRIALS research · 2025-04-02Clinical Trial Update: Exploratory Biomarker Analysis of Neoadjuvant Chemoimmunotherapy Followed by Pulmonary Resection in Stage II-III Non-Small Cell Lung Cancer
This clinical trial update indicates ongoing recruitment for an exploratory biomarker analysis of neoadjuvant chemoimmunotherapy followed by…
-
CLINICAL_TRIALS other · 2025-04-02Clinical Trial Update: TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (Rx)
The trial is sponsored by University College London and aims to track the evolution of Non-small cell lung cancer through therapy. It is cur…
-
CLINICAL_TRIALS trial_result · 2025-04-01Clinical Trial Update: Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer [Phase 2]
Phase 2 trial evaluating binimetinib in combination with hydroxychloroquine for advanced KRAS-mutant non-small cell lung cancer has complete…
-
CLINICAL_TRIALS trial_result · 2025-04-01Clinical Trial Update: Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer [Phase 2]
Phase 2 trial evaluating lorlatinib in patients with advanced ALK-positive non-small cell lung cancer after progression on first-line second…
-
CLINICAL_TRIALS trial_result · 2025-04-01Clinical Trial Update: Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung Cancer [NA]
A completed trial evaluated whether hypofractionated radiation therapy can enhance immunotherapy response in metastatic non-small cell lung …
-
CLINICAL_TRIALS research · 2025-04-01Clinical Trial Update: Toripalimab Therapy After Resection in High-risk Stage IA2-IB NSCLC With no Driver Alterations (EGFR or ALK) [Phase 2]
A Phase 2 trial evaluating toripalimab as postoperative therapy after surgical resection in high-risk stage IA2-IB non-small cell lung cance…
-
CLINICAL_TRIALS research · 2025-04-01Clinical Trial Update: De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction [Phase 2, Phase 3]
A Phase 2/Phase 3 clinical trial is evaluating whether de-escalating the duration of maintenance immunotherapy benefits patients with stage …